HS
JBIO

HighVista Strategies’s Jade Biosciences JBIO Stock Holding History

HighVista Strategies’s Portfolio JBIO Stock Details JBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-1,194
Closed -$717K – 138
2023
Q2 		$717K Buy
1,194
+742
+164% +$475K 0.33% 85
2023
Q1 		$319K Buy
+452
New +$375K 0.26% 89

Other funds holding JBIO

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

HighVista Strategies's JBIO Position: Q3 2023 in Review

HighVista Strategies sold out of Jade Biosciences (JBIO) in Q3 2023, closing a stake of 1,194 shares — an estimated $717K sold.

HighVista Strategies first reported a position in JBIO in Q1 2023 and held it in 2 quarters. The position peaked at $717K in Q2 2023. 58 funds tracked by Wall St. Rank hold JBIO as of Q3 2023.

  • HighVista Strategies reported no remaining Jade Biosciences position as of Q3 2023 after selling out during the quarter.
  • HighVista Strategies sold 1,194 Jade Biosciences shares in Q3 2023, an estimated $717K.
  • HighVista Strategies first reported a position in Jade Biosciences in Q1 2023 and held it in 2 quarters.
  • HighVista Strategies's Jade Biosciences position peaked at $717K in Q2 2023.
  • 58 funds tracked by Wall St. Rank held Jade Biosciences as of Q3 2023.

Based on HighVista Strategies's 13F filing for Q3 2023, filed 14 Nov 2023.